View More View Less
  • 1 Országos Onkológiai Intézet Nőgyógyászati Osztálya Budapest Ráth Gy. u. 7–9. 1122
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Bevezetés: A daganatos betegek kemoterápiája kapcsán fellépő anémia miatt adott erythropoetin-kezelések ritka velejárója a trombózis. Az epoetint gyártó cégek valamennyi ilyen készítmény ismertetőjében felhívják a figyelmet erre az esetleges mellékhatásra. Cél: A petefészekrákos betegek kemoterápiája kapcsán adott epoetinkezelések során fellépő thromboticus események áttekintése. Anyag és módszer: Az Országos Onkológiai Intézet Nőgyógyászati osztályán a 2000 és 2006 közötti időszakban 275 petefészekrákos beteg közül 52 kapott epoetin-alfa, 157 epoetin-béta, 66 beteg pedig darbepoetin-alfa-kezelést. A betegek életkora medián 60 (szélső értékek 22, 84) év volt. Eredmény: A 275 közül 1 betegben epoetin-alfa-, 2 betegben pedig epoetin-béta-kezelés kapcsán figyeltek meg thromboticus eseményt (3/275 = 1,1%). A kialakult trombózisok és az epoetinkezelés közötti egyértelmű okozati összefüggést igazolni nem sikerült. Következtetés: A nagy irodalmi metaanalízisekkel megegyezően a szerzők beteganyagában is csak igen ritka a kezelés kapcsán fellépett trombózis.

  • Borbényi, Z.: A daganatos betegségekhez társuló anémiák okai és kezelési lehetőségei. Magyar Onkológia, 2001, 45 , 437–441.

    Borbényi Z. , 'A daganatos betegségekhez társuló anémiák okai és kezelési lehetőségei ' (2001 ) 45 Magyar Onkológia : 437 -441.

    • Search Google Scholar
  • Ludwig, H., Strasser, K.: Symptomatology of anemia. Semin. Oncol., 2001, 28 (suppl. 8) , 7–14.

    Strasser K. , 'Symptomatology of anemia ' (2001 ) 28 Semin. Oncol. : 7 -14.

  • Waters, J. S., O’Brien, M. E. R., Ashley, S.: Management of anemia in patients receiving chemotherapy. J. Clin. Oncol., 2002, 20 , 601–603.

    Ashley S. , 'Management of anemia in patients receiving chemotherapy ' (2002 ) 20 J. Clin. Oncol. : 601 -603.

    • Search Google Scholar
  • Ludwig, H. az ECAS Tanácsadó Testülete és résztvevői nevében: European Cancer Anaemia Survey (ECAS): How big is the problem? Az „Újdonságok a rákos vérszegénység kezelésében – 3. Oktatási Szimpózium” absztraktjai. Orthobiotech, Wien, 2003, 6.

  • Barrett-Lee, P., Bokemeyer, C., Gascon, P., ECAS Advisory Board and Participating Centers: Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist, 2005, 10 , 743–757.

    Gascon P. , 'Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey ' (2005 ) 10 Oncologist : 743 -757.

    • Search Google Scholar
  • Littlewood, T. J., Bajetta, E., Nortier, J. W. R. és mtsai az Epoetin Alfa Vizsgáló Csoportból: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol., 2001, 19 , 2865–2874.

    Nortier J. W. R. , 'Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial ' (2001 ) 19 J. Clin. Oncol. : 2865 -2874.

    • Search Google Scholar
  • Boogaerts, M., Oberhoff, C., Ten Bokkel Huinink, W. és mtsai: Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis. Anticancer Res., 2006, 26 (1B) , 479–484.

    Bokkel Huinink W. , 'Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis ' (2006 ) 26 Anticancer Res. : 479 -484.

    • Search Google Scholar
  • Ludwig, H., Van Belle, S., Barrett-Lee, P. és mtsai: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer, 2004, 40 , 2293–2306.

    Barrett-Lee P. , 'The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients ' (2004 ) 40 Eur. J. Cancer : 2293 -2306.

    • Search Google Scholar
  • Láng, I.: Újabb klinikai adatok a daganatos betegek anémiájának erytropoetin kezelésében. Magy. Onkol., 2005, 49 , 251–254.

    Láng I. , 'Újabb klinikai adatok a daganatos betegek anémiájának erytropoetin kezelésében ' (2005 ) 49 Magy. Onkol. : 251 -254.

    • Search Google Scholar
  • Oncologic Drugs Advisory Committee 2004. évi jelentése (Letöltve 2007. 05. 01-én): http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037B2_04_FDA-Aranesp-Procrit.doc . – 11

  • Lin, F. K., Suggs, S., Lin, C. H. és mtsai: Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA, 1985, 82 , 7580–7582.

    Lin C. H. , 'Cloning and expression of the human erythropoietin gene ' (1985 ) 82 Proc. Natl. Acad. Sci. USA : 7580 -7582.

    • Search Google Scholar
  • Donati, M. B.: Cancer and thrombosis. Haemostasis, 1994, 24 , 128–131.

    Donati M. B. , 'Cancer and thrombosis ' (1994 ) 24 Haemostasis : 128 -131.

  • Levitan, N., Dowlati, A., Remick, S. C.: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore), 1999, 78 , 285–291.

    Remick S. C. , 'Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data ' (1999 ) 78 Medicine (Baltimore) : 285 -291.

    • Search Google Scholar
  • Heit, J. A., Silverstein, M. D., Mohr, D. N. és mtsai: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med., 2000, 160 , 809–815.

    Mohr D. N. , 'Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study ' (2000 ) 160 Arch. Intern. Med. : 809 -815.

    • Search Google Scholar
  • Matsuura, Y., Robertson, G., Marsden, D. E. és mtsai: Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol. Oncol., 2007, 104 , 406–410.

    Marsden D. E. , 'Thromboembolic complications in patients with clear cell carcinoma of the ovary ' (2007 ) 104 Gynecol. Oncol. : 406 -410.

    • Search Google Scholar
  • Tateo, S., Mereu, L., Salamano, S. és mtsai: Ovarian cancer and venous thromboembolic risk. Gynecol. Oncol., 2005, 99 , 119–125.

    Salamano S. , 'Ovarian cancer and venous thromboembolic risk ' (2005 ) 99 Gynecol. Oncol. : 119 -125.

    • Search Google Scholar
  • Canon, J. L., Vansteenkiste, J., Bodoky, G. és mtsai: Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J. Natl. Cancer. Inst., 2006, 98 , 273–284.

    Bodoky G. , 'Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia ' (2006 ) 98 J. Natl. Cancer. Inst. : 273 -284.

    • Search Google Scholar
  • Ross, S. D., Allen, I. E., Henry, D. H. és mtsai: Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin. Ther., 2006, 28 , 801–831.

    Henry D. H. , 'Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature ' (2006 ) 28 Clin. Ther. : 801 -831.

    • Search Google Scholar
  • Bohlius, J., Wilson, J., Seidenfeld, J.: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev., 2006, Jul., 19, 3 , CD003407.

    Seidenfeld J. , 'Erythropoietin or darbepoetin for patients with cancer ' (2006 ) 19 Cochrane Database Syst. Rev. : CD003407 -.

    • Search Google Scholar
  • Bohlius, J., Wilson, J., Seidenfeld, J. és mtsai: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst., 2006, 98 , 708–714.

    Seidenfeld J. , 'Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients ' (2006 ) 98 J. Natl. Cancer Inst. : 708 -714.

    • Search Google Scholar
  • Westin, S. N., Skinner, E. N., Jonsson, F. M. és mtsai: Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer. Gynecol. Oncol., 2007, 105 , 414–417.

    Jonsson F. M. , 'Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer ' (2007 ) 105 Gynecol. Oncol. : 414 -417.

    • Search Google Scholar
  • Aapro, M., Coiffier, B., Dunst, J. és mtsai: Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis. Br. J. Cancer., 2006, 95 , 1467–1473.

    Dunst J. , 'Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis ' (2006 ) 95 Br. J. Cancer. : 1467 -1473.

    • Search Google Scholar
  • Coiffier, B., Boogaerts, M., Aaapro, M. és mtsai: Effect of treatment with epoetin beta on thromboembolic events in anemic patients with cancer: a metaanalysis. Support. Cancer Ther., 2006, 4 , 49–55.

    Aaapro M. , 'Effect of treatment with epoetin beta on thromboembolic events in anemic patients with cancer: a metaanalysis ' (2006 ) 4 Support. Cancer Ther. : 49 -55.

    • Search Google Scholar
  • Henke, M., Laszig, R., Rube, C. és mtsai: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 2003, 362 (9392) , 1255–1260.

    Rube C. , 'Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial ' (2003 ) 362 Lancet : 1255 -1260.

    • Search Google Scholar
  • Leyland-Jones, B. a BEST kutatók és munkacsoport nevében: Breast cancer trial with erythopoietin terminated unexpectedly. Lancet Oncology, 2003, 4 , 459–460.

    Leyland-Jones B. , 'Breast cancer trial with erythopoietin terminated unexpectedly ' (2003 ) 4 Lancet Oncology : 459 -460.

    • Search Google Scholar
  • Wright, J. R., Ung, Y. C., Julian, J. A. és mtsai: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol., 2007, 25 , 1027–1032.

    Julian J. A. , 'Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia ' (2007 ) 25 J. Clin. Oncol. : 1027 -1032.

    • Search Google Scholar
  • FDA ajánlás: http://www.fda.gov/cder/drug/infopage/RHE/default.htm . (Megjelenés ideje: 2007. március 9. Letöltés ideje: 2007. május 6.)

  • Henke, M., Mattern, D., Pepe, M. és mtsai: Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J. Clin. Oncol., 2006, 24 , 4708–4713.

    Pepe M. , 'Do erythropoietin receptors on cancer cells explain unexpected clinical findings? ' (2006 ) 24 J. Clin. Oncol. : 4708 -4713.

    • Search Google Scholar
  • Pronzato, P., Jassem, J., Mayordomo, J.: Epoetin beta therapy in patients with solid tumours. Crit. Rev. Oncol. Hematol., 2006, 58 , 46–52.

    Mayordomo J. , 'Epoetin beta therapy in patients with solid tumours ' (2006 ) 58 Crit. Rev. Oncol. Hematol. : 46 -52.

    • Search Google Scholar
  • Bokemeyer, C., Aapro, M. S., Courdi, A. és mtsai: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur. J. Cancer, 2007, 43 , 258–270.

    Courdi A. , 'EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update ' (2007 ) 43 Eur. J. Cancer : 258 -270.

    • Search Google Scholar
  • Wilson, J., Yao, G. L., Raftery, J. és mtsai: A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol. Assess., 2007, 11 , 1–220.

    Raftery J. , 'A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment ' (2007 ) 11 Health Technol. Assess. : 1 -220.

    • Search Google Scholar

 

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

 

Mendeley citation style is available HERE.
  • Impact Factor (2019): 0.497
  • Scimago Journal Rank (2018): 0.176
  • SJR Hirsch-Index (2018): 20
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)
  • Impact Factor (2018): 0.564
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu